Role of biomarkers in Cardiac Arrhythmia in Children | ||||
| Benha Journal of Applied Sciences | ||||
| Article 14, Volume 9, Issue 7, July 2024, Page 55-60 PDF (353.59 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/bjas.2024.303093.1453 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Marwa Mohamed Hegazy  1; Doaa Refaey Soliman2; Eman Gamal Abd-El Rahman3; Seham Gouda Ameen4; Ahmed Nabih El Shazly3
| ||||
| 1Zagazig Sharqia | ||||
| 2Pediatric department, Benha faculty of medicine, Benha University, Egypt. | ||||
| 3Department of Pediatrics, Faculty of Medicine, Benha University, Benha, Egypt | ||||
| 4Department of Clinical and Chemical Pathology, Faculty of Medicine, Benha University, Benha, Egypt | ||||
| Abstract | ||||
| Background: The burden of pediatric cardiac arrhythmias is variable and can lead to morbidity and mortality. Many biomarkers are related to cardiovascular diseases. Fibroblast growth factor 23 (FGF-23) is an example for important biomarkers in arrhythmia. It is formed in bone and is related to mineral bone metabolism. Elevated levels of this factor were correlated with chronic renal disease and many cardiovascular diseases. Many studies correlated FGF-23 with arrhythmia particularly atrial fibrillation and revealed that it may be used as a prognostic biomarker in those patients. Knowledge of FGF-23 role in cardiovascular problems may be used to discover new methods in management of these disorders. Objective: The aim of this review is to shed light on pediatric cardiac arrhythmia and to study the importance of biomarkers in cardiovascular diseases particularly cardiac arrhythmia and study its relationship with prognosis and cardiac function. Keywords: Fibroblast growth factor-23, Cardiac arrhythmia, Biomarkers, Atrial fibrillation. | ||||
| Keywords | ||||
| Fibroblast growth factor-23; Cardiac arrhythmia; Biomarkers; Atrial fibrillation | ||||
|
Statistics Article View: 188 PDF Download: 191 |
||||
